- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | PLRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | REX | PLRX |
|---|---|---|
| Price | $34.32 | $1.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | ★ $25.00 | $3.79 |
| AVG Volume (30 Days) | 217.5K | ★ 1.9M |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $650,756,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $22.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.73 | $1.10 |
| 52 Week High | $36.50 | $15.00 |
Technical Indicators
Market Signals| Indicator | REX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 35.31 |
| Support Level | $33.04 | $1.19 |
| Resistance Level | $34.66 | $1.35 |
| Average True Range (ATR) | 1.57 | 0.12 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 51.20 | 16.35 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.